SCHEMBL616606

SCHEMBL616606

Fc1cc(F)c2nc[nH]c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
PNP P00491 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PRNP P04156 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
ACLY P53396 1/20 0.39
PARP1 P09874 1/20 0.35
IP6K1 Q92551 1/20 0.35
LMNA P02545 2/20 0.34
IDO1 P14902 1/20 0.34
KDM4E B2RXH2 1/20 0.33
APEX1 P27695 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
HTR6 P50406 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316449 0.79 MAPT (0.39) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL14723169 0.79 MEN1 (0.49) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL7922229 0.79 MEN1 (0.44) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL539263 0.79 PARP1 (0.41) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL1144726 0.79 MEN1 (0.44) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL29804933 0.79 MEN1 (0.44) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL6956986 0.78 MAPT (0.46) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL19141612 0.75 PNP (0.39) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL30477591 0.75 CTSS (0.38) MAPTPNPMEN1KMT2AALDH1A1
SCHEMBL12277149 0.75 MAPT (0.36) MAPTPNPMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023143247-A1 LINKER FOR CHARACTERIZING SEQUENCING OF TARGET POLYNUCLEOTIDE, CONSTRUCT, METHOD, AND USE 成都齐碳科技有限公司 2023-08-03 WO claimed
CN-114457145-A Linkers, constructs, methods, and uses for characterizing sequencing of target polynucleotides 成都齐碳科技有限公司 2022-05-10 CN claimed
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF UNIV DE MONTREAL (CA) 2026-05-21 US disclosed
CN-122036621-A Fluorine substituted benzimidazolyl aniline compound and synthetic method and application thereof 中茂绿能科技(西安)有限公司 2026-05-15 CN disclosed
WO-2026090491-A1 ENHANCED DELIVERY OF DISEASE-TARGETED NANOBODY-SIRNA CONJUGATES OHIO STATE INNOVATION FOUNDATION (US) 2026-04-30 WO disclosed
US-12559766-B2 Peanut with reduced allergen levels INGATEYGEN LLC (US) 2026-02-24 US disclosed
US-12404274-B2 Macrocycles as factor xia inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-02 US disclosed
EP-4602047-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF The Universite de Montreal (CA) 2025-08-20 EP disclosed
EP-3327140-B1 CAPTURE PROBES IMMOBILIZABLE VIA L-NUCLEOTIDE TAIL GEN PROBE INC (US) 2025-08-06 EP disclosed
CN-120035595-A Thiazolo [5,4-d ] pyrimidine compounds, compositions comprising the same and uses thereof 蒙特利尔大学 2025-05-23 CN disclosed
US-20250136658-A1 ANTICONVULSANT AND NEUROPROTECTIVE AGENT THE UAB RESEARCH FOUNDATION 2025-05-01 US disclosed
US-20120041190-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-02-16 US disclosed
WO-2011100401-A1 MACROCYCLES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-08-18 WO disclosed
EP-2069536-A1 METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS Gen-Probe Incorporated (US) 2009-06-17 EP disclosed
US-7504513-B2 Thiazolyl-benzimidazoles HOFFMAN-LA ROCHE INC. (US) 2009-03-17 US disclosed
US-7504513-B2 Thiazolyl-benzimidazoles HOFFMAN-LA ROCHE INC. (US) 2009-03-17 US disclosed
US-20080286775-A1 METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS GEN-PROBE INCORPORATED (US) 2008-11-20 US disclosed
WO-2008016988-A1 METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS GEN-PROBE INCORPORATED (US) 2008-02-07 WO disclosed
US-20070203210-A1 Thiazolyl-benzimidazoles BOYLAN JOHN FREDERICK 2007-08-30 US disclosed
US-20070203210-A1 Thiazolyl-benzimidazoles BOYLAN JOHN FREDERICK 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041190-A1 MACROCYCLES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F11 MAPT 326/4885PNP 4526/4885MEN1 376/4885
US-12404274-B2 Macrocycles as factor xia inhibitors TFPI, TFPI2, F11 MAPT 326/4885PNP 4526/4885MEN1 376/4885
US-20070203210-A1 Thiazolyl-benzimidazoles CYP3A7, CYP2C19, CYP3A5 MAPT 1573/4885PNP 1418/4885MEN1 557/4885
US-12559766-B2 Peanut with reduced allergen levels H1-2, CPA2, RNASEH1 MAPT 2600/4885PNP 1667/4885MEN1 4877/4885
US-20260137697-A1 THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF NRAS, KRAS, BRAF MAPT 4264/4885PNP 2000/4885MEN1 3244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.